2PEYVANDI F,SPREAFICO M,SIBONI S M,et al.CYP2C9 genotypes and does requirements during the induction phase of oral anticogulant therapy[J].Clin Pharmacol Ther,2004,75(3):198-203.
4LEE C R,GOLDSTEIN J,PIEPER J A.Cytochrom P450 2C9 polymorphisms:a comprehensive review of the in-vitro and human data[J].Pharmacogenetics,2002,12(3):251-263.
5XIE H G,PRASAD H C,KIM R B,et al.CYP2C9 allelic variants:ethnic distribution and functional significance[J].Adv Drug Deliv Rev,2002,54(10):1257-1270.
6ALLABI A C,GALAJL,HORSMANSY,etal.Functional impact of CYP2C9* 5,CYP2C9*6,CYP2C9* 8,and CYP2C9* 11 in viv among black Africans[J].Clin Pharmacol Ther,2004,76(2):113-118.
7SCORDO M G,PENGO V,SPINA E,et al.Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance[J].Chin Pharmacol Ther,2002,72 (6):702 -710.
8VANDER WEIDE J,STEIJNS L S,VAN WEELDEN M J,et al.The effect of genetic polymorphism CYP2C9 on phenytoin dose requirement[J].Pharmacogenetios,2001,11 (4):287-291.
9NIEMI M,CASCORBI I,TIMM R,et al.Glyburide and glimepiride pharmacokinrtics subjects with different CYP2C9 genotypes[J].Clin Pharmacol Ther,2002,72(3):326-332.
10JETTER A,KINZIG-SCHIPPERS M,SKOTT A L,et al.CYP2C9 phenotying using loe-dose tolbutamide[J].Eur J clin Pharmacol,2004,60(3):165-171.
